These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32218009)

  • 21. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.
    Nadolsky KZ
    Mil Med; 2018 Mar; 183(3-4):45-50. PubMed ID: 29420770
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of obesity in 2015.
    Shukla AP; Buniak WI; Aronne LJ
    J Cardiopulm Rehabil Prev; 2015; 35(2):81-92. PubMed ID: 25714749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender-related issues in the pharmacology of new anti-obesity drugs.
    Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
    Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Rubio MA
    Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
    [No Abstract]   [Full Text] [Related]  

  • 27. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G; Cheng-Lai A
    Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
    Grunvald E; Shah R; Hernaez R; Chandar AK; Pickett-Blakely O; Teigen LM; Harindhanavudhi T; Sultan S; Singh S; Davitkov P;
    Gastroenterology; 2022 Nov; 163(5):1198-1225. PubMed ID: 36273831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of medications approved for chronic weight management.
    Fujioka K
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapies for obesity and medication-associated weight gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 May; 51(5):13-6. PubMed ID: 23590816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New developments in the pharmacologic treatment of obesity.
    Fantasia HC
    Nurs Womens Health; 2013; 17(1):53-62. PubMed ID: 23399013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
    Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
    Brown SA; Izzy M; Watt KD
    Hepatology; 2021 May; 73(5):2051-2062. PubMed ID: 33047343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New medications for obesity management: changing the landscape of obesity treatment.
    Boulghassoul-Pietrzykowska N; Franceschelli J; Still C
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):407-11. PubMed ID: 23974768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New pharmacological approaches for obesity management.
    Rueda-Clausen CF; Padwal RS; Sharma AM
    Nat Rev Endocrinol; 2013 Aug; 9(8):467-78. PubMed ID: 23752772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.